Trial-results highlights
Avacopan has been investigated in a pivotal clinical trial known as ADVOCATE, which is officially registered under the identifier NCT02994927. This study focused on patients diagnosed with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, a specific type of autoimmune disease. One of the primary objectives of the ADVOCATE trial was to evaluate the percentage of participants who achieved disease remission at Week 26. In the Avacopan treatment arm of NCT02994927, **72.3 percentage** of participants were reported to have achieved disease remission. In the comparator prednisone treatment arm of the same trial, NCT02994927, **70.1 percentage** of participants achieved disease remission at the Week 26 assessment point.
The ADVOCATE trial (NCT02994927) also assessed a longer-term outcome: the percentage of subjects who achieved sustained disease remission at Week 52. This endpoint aimed to understand the durability of the treatment effect. For participants receiving Avacopan in NCT02994927, **65.7 percentage** achieved sustained disease remission at Week 52. In the prednisone group of NCT02994927, **54.9 percentage** of participants achieved sustained disease remission at Week 52. These results from the ADVOCATE trial provide insights into the effects of Avacopan in managing Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis over both a short-term and a longer-term period.
All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.